First-Line Management of Irregular Per-Vaginal Bleeding
The first-line treatment for irregular per-vaginal bleeding in reproductive-age women is the levonorgestrel-releasing intrauterine system (LNG-IUS), which provides the most effective reduction in menstrual blood loss, followed by antifibrinolytics (tranexamic acid) and combined oral contraceptives as alternative options. 1, 2
Initial Assessment Requirements
Before initiating treatment, you must rule out:
- Pregnancy (mandatory testing in all reproductive-age women)
- Sexually transmitted infections (cervicitis, chlamydia, gonorrhea)
- Thyroid disorders (TSH levels)
- New pathologic uterine conditions (polyps, fibroids via transvaginal ultrasound)
- Coagulopathies (particularly in adolescents or those with bleeding since menarche)
- Medication interactions 1, 3
Endometrial biopsy is indicated for:
- Women ≥35 years with recurrent anovulation
- Women <35 years with risk factors for endometrial cancer
- Excessive bleeding unresponsive to medical therapy 4
Evidence-Based Treatment Algorithm
First-Line Medical Options (in order of effectiveness):
1. LNG-IUS (Levonorgestrel Intrauterine System) - MOST EFFECTIVE
- Reduces menstrual blood loss by 105.71 mL/cycle (95% CI -201.10 to -10.33)
- Mean rank 2.4 (best among first-line treatments)
- Achieves 71-95% reduction in bleeding
- Low certainty evidence but strongest effect size 1, 2, 5
2. Tranexamic Acid (Antifibrinolytics) - SECOND BEST
- Reduces menstrual blood loss by 80.32 mL/cycle (95% CI -127.67 to -32.98)
- Mean rank 3.7
- Moderate certainty evidence
- Treatment duration: 5 days during bleeding 1, 2
3. Combined Oral Contraceptives (COCs)
- Long-cycle progestogens reduce MBL by 76.93 mL/cycle
- Mean rank 4.1
- Low certainty evidence
- Can be used for 10-20 days for acute bleeding control 1, 2
4. NSAIDs (Least Effective Medical Option)
- Reduces MBL by 40.67 mL/cycle (95% CI -84.61 to 3.27)
- Mean rank 6.4
- Treatment duration: 5-7 days during bleeding
- Can be combined with hormonal methods 1, 2
Treatment Strategy Based on Clinical Context
For Contraception-Related Irregular Bleeding:
If already using contraception and experiencing breakthrough bleeding 1:
- Cu-IUD users: NSAIDs 5-7 days
- Implant users: NSAIDs 5-7 days for light bleeding; for heavy bleeding add low-dose COCs or estrogen 10-20 days, or tranexamic acid 5 days
- DMPA users: NSAIDs 5-7 days
- CHC users (extended regimen): Hormone-free interval 3-4 days (not during first 21 days, max once monthly)
For Non-Contraceptive-Related Bleeding:
Anovulatory bleeding (irregular, unpredictable):
- Combined oral contraceptives or cyclic progestins to regulate cycles
- If hyperplasia without atypia found: continuous or cyclic progestin
- Refer to gynecology if hyperplasia with atypia 3, 4
Ovulatory bleeding (regular but heavy - menorrhagia):
- LNG-IUS as first choice
- Tranexamic acid as alternative
- Oral progestins for 21 days per month
- NSAIDs as adjunct 4
Critical Pitfalls to Avoid
Do NOT delay pregnancy testing - all reproductive-age women must be tested before treatment initiation 1
Do NOT use NSAIDs or tranexamic acid in women with cardiovascular disease (particularly spontaneous coronary artery dissection) due to MI and thrombosis risk 5
Do NOT place IUD if active purulent cervicitis or gonorrhea/chlamydia infection present (U.S. MEC Category 4) 1
Do NOT assume hormonal contraception failure means treatment failure - provide reassurance that irregular bleeding is common and generally not harmful, especially in first year of use 6
Do NOT overlook bleeding disorders - consider von Willebrand disease in women with heavy bleeding since menarche 4, 7
When Medical Management Fails
If bleeding persists despite appropriate medical therapy or patient finds it unacceptable:
- Perform hysteroscopy to visualize endometrial cavity
- Consider saline infusion sonohysterography (96-100% sensitivity for uterine pathology)
- Offer second-line treatments: endometrial ablation or hysterectomy (only when fertility no longer desired) 3, 2
The strength of this recommendation is based on the 2024 CDC guidelines 1 and the 2022 Cochrane network meta-analysis 2, which represent the most recent and comprehensive evidence available, though individual treatment certainty ranges from moderate to low.